Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.04. This compares to loss of $2.65 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.78%. A quarter ago, it was expected that this cancer drug developer would post a loss of $2.39 per share when it actually produced a loss of $2.20, delivering a surprise of 7.95%.Over the last four quarters, the com ...